KAZUO KOYANAGI

Prof. Dr. KAZUO KOYANAGI

Department of Gastroenterological Surgery, Tokai University School of Medicine

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Medicine
Verified
Journal Article
Open access
KKKAZUO KOYANAGI
KAZUO KOYANAGI
SOSoji Ozawa
Soji Ozawa
JOJunya Oguma
Junya Oguma
AKAkihito Kazuno
Akihito Kazuno
YYYasushi Yamazaki
Yasushi Yamazaki
YTYuji Tachimori
Yuji Tachimori
Anastomotic leakage is considered as an independent risk factor for postoperative mortality after esophagectomy, and an insufficient blood flow in the reconstructed conduit may be a risk factor of anastomotic leakage. We investigated the clinical significance of blood flow visualization by indocyanine green (ICG) fluorescence in the gastric conduit as a means of predicting the leakage of esophagogastric anastomosis after esophagectomy. Forty patients who underwent an esophagectomy with gastric conduit reconstruction were prospectively investigated. ICG fluorescence imaging of the gastric conduit was detected by a near-infrared camera system during esophagectomy and correlated with clinical parameters or surgical outcomes. In 25 patients, the flow speed of ICG fluorescence in the gastric conduit wall was simultaneous with that of the greater curvature vessels (simultaneous group), whereas in 15 patients this was slower than that of the greater curvature vessels (delayed group). The reduced speed of ICG fluorescence stream in the gastric conduit wall was associated with intraoperative blood loss (P = 0.008). Although anastomotic leakage was not found in the simultaneous group, it occurred in 7 patients of the delayed group (P < 0.001). A flow speed of ICG fluorescence in the gastric conduit wall of 1.76 cm/s or less was determined by a receiver operating characteristic (ROC) curve, identified as a significant independent predictor of anastomotic leakage after esophagectomy (P = 0.004). This preliminary study demonstrates that intraoperative evaluation of blood flow speed by ICG fluorescence in the gastric conduit wall is a useful means to predict the risk of anastomotic leakage after esophagectomy.

21 May 2024 in World Journal of Gastroenterology
Verified
Journal Article
Open access
YSYoshiaki Shoji
Yoshiaki Shoji
KKKAZUO KOYANAGI
KAZUO KOYANAGI
KKKohei Kanamori
Kohei Kanamori
KTKohei Tajima
Kohei Tajima
MOMika Ogimi
Mika Ogimi
MMMasaki Mori
Masaki Mori
Immune checkpoint inhibitor therapy has dramatically improved patient prognosis, and thereby transformed the treatment in various cancer types including esophageal squamous cell carcinoma (ESCC) in the past decade. Monoclonal antibodies that selectively inhibit programmed cell death-1 (PD-1) activity has now become standard of care in the treatment of ESCC in metastatic settings, and has a high expectation to provide clinical benefit during perioperative period. Further, anti-cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) monoclonal antibody has also been approved in the treatment of recurrent/metastatic ESCC in combination with anti-PD-1 antibody. Well understanding of the existing evidence of immune-based treatments for ESCC, as well as recent clinical trials on various combinations with chemotherapy for different clinical settings including neoadjuvant, adjuvant, and metastatic diseases, may provide future prospects of ESCC treatment for better patient outcomes.

12 February 2020 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
SOSoji Ozawa
Soji Ozawa
KKKAZUO KOYANAGI
KAZUO KOYANAGI
YNYamato Ninomiya
Yamato Ninomiya
KYKentaro Yatabe
Kentaro Yatabe
THTadashi Higuchi
Tadashi Higuchi
Minimally invasive esophagectomy (MIE) has been performed increasingly more frequently for the treatment of esophageal cancer, ever since it was first described in 1992. However, the incidence of postoperative complications of MIE has not yet been well‐characterized, because (a) there are few reports of studies with a sufficient sample size, (b) a variety of minimally invasive surgical techniques are used, and (c) there are few reports in which an established system for classifying the severity of complications is examined. According to an analysis performed by the Esophageal Complications Consensus Group, the most common complications of MIE are pneumonia, arrhythmia, anastomotic leakage, conduit necrosis, chylothorax, and recurrent laryngeal nerve palsy. Therefore, we decided to focus on these complications. We selected 48 out of 1245 reports of studies (a) that included more than 50 patients each, (b) in which the esophagectomy technique used was clearly described, and (c) in which the complications were adequately described. The overall incidences of the postoperative complications of MIE for esophageal cancer were analyzed according to the MIE technique adopted, that is, McKeown MIE, Ivor Lewis MIE, robotic‐assisted McKeown MIE, robotic‐assisted Ivor Lewis MIE, or mediastinoscopic transmediastinal esophagectomy. Pneumonia, arrhythmia, anastomotic leakage, and recurrent laryngeal nerve palsy occurred at an incidence rate of about 10% each; Ivor Lewis MIE was associated with a relatively low incidence of recurrent laryngeal nerve palsy. It is important to recognize that the incidences of complications of MIE are influenced by the MIE technique adopted and the extent of lymph node dissection.

10 April 2018 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
KKKAZUO KOYANAGI
KAZUO KOYANAGI
FKFumihiko Kato
Fumihiko Kato
JKJun Kanamori
Jun Kanamori
HDHiroyuki Daiko
Hiroyuki Daiko
SOSoji Ozawa
Soji Ozawa
YTYuji Tachimori
Yuji Tachimori
Aim: This study investigated whether esophageal invasion length (EIL) of a tumor from the esophagogastric junction could be a possible indicator of mediastinal lymph node metastasis and survival in patients with Siewert type II adenocarcinoma.Methods: One hundred and sixty‐eight patients with Siewert type II tumor who underwent surgery were enrolled. Metastatic stations and recurrent lymph node sites were classified into cervical, upper/middle/lower mediastinal, and abdominal zones. EIL was correlated with overall metastasis or recurrence in individual zones and with survival.Results: Siewert type II patients with an EIL of more than 25 mm (>25 mm EIL group) had a higher incidence of overall metastasis or recurrence in the upper and middle mediastinal zones than those with an EIL of less than or equal to 25 mm (≤25 mm EIL group) (P = .001 and P < .001). Disease‐free and overall survival in the >25 mm EIL group were significantly lower than those of the ≤25 mm EIL group (P < .001). None of the Siewert type II patients with metastasis or recurrence in the upper and middle mediastinal zones survived for more than 5 years. Only an EIL of more than 25 mm was a significant preoperative predictor of overall metastasis or recurrence in the upper and middle mediastinal zones (odds ratio, 8.85; 95% CI, 2.31‐33.3; P = .001).Conclusion: A multimodal‐therapeutic strategy should be investigated in Siewert type II patients once the tumor has invaded more than 25 mm to the esophageal wall.

10 April 2015 in Surgery Today
Verified
Journal Article
Closed access
PDF file
KKKAZUO KOYANAGI
KAZUO KOYANAGI
SOSoji Ozawa
Soji Ozawa
YTYuji Tachimori
Yuji Tachimori

11 May 2021 in Surgery Today
Verified
Journal Article
Closed access
PDF file
KKKAZUO KOYANAGI
KAZUO KOYANAGI
SOSoji Ozawa
Soji Ozawa
YNYamato Ninomiya
Yamato Ninomiya
KYKentaro Yatabe
Kentaro Yatabe
THTadashi Higuchi
Tadashi Higuchi
KTKohei Tajima
Kohei Tajima